Article Type
Changed
Thu, 01/06/2022 - 08:51

Key clinical point: Transgluteal CT-guided biopsy identified prostate cancer lesions in men without rectal access with no major complications reported.

Major finding: A total of 4 lesions were targeted using anatomic landmarks and 5 were targeted using contrast enhancement. All biopsies using transgluteal CT were technically successful and identified as prostate cancer. A total of 3 biopsies showed Gleason 6 cancer, and 6 biopsies showed clinically significant prostate cancers with Gleason 7 or above; a total of 7 patients underwent definitive treatment with surgery or radiation.

Study details: The data come from a retrospective study of 9 prostate cancer patients without rectal access who underwent transgluteal CT-guided biopsy between May 2016 and February 2021. The two targeting techniques were localizing with anatomic landmarks or localizing with contrast enhancement.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Patel N et al. Clin Imaging. 2021 Jun 9. doi: 10.1016/j.clinimag.2021.06.004.

Publications
Topics
Sections

Key clinical point: Transgluteal CT-guided biopsy identified prostate cancer lesions in men without rectal access with no major complications reported.

Major finding: A total of 4 lesions were targeted using anatomic landmarks and 5 were targeted using contrast enhancement. All biopsies using transgluteal CT were technically successful and identified as prostate cancer. A total of 3 biopsies showed Gleason 6 cancer, and 6 biopsies showed clinically significant prostate cancers with Gleason 7 or above; a total of 7 patients underwent definitive treatment with surgery or radiation.

Study details: The data come from a retrospective study of 9 prostate cancer patients without rectal access who underwent transgluteal CT-guided biopsy between May 2016 and February 2021. The two targeting techniques were localizing with anatomic landmarks or localizing with contrast enhancement.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Patel N et al. Clin Imaging. 2021 Jun 9. doi: 10.1016/j.clinimag.2021.06.004.

Key clinical point: Transgluteal CT-guided biopsy identified prostate cancer lesions in men without rectal access with no major complications reported.

Major finding: A total of 4 lesions were targeted using anatomic landmarks and 5 were targeted using contrast enhancement. All biopsies using transgluteal CT were technically successful and identified as prostate cancer. A total of 3 biopsies showed Gleason 6 cancer, and 6 biopsies showed clinically significant prostate cancers with Gleason 7 or above; a total of 7 patients underwent definitive treatment with surgery or radiation.

Study details: The data come from a retrospective study of 9 prostate cancer patients without rectal access who underwent transgluteal CT-guided biopsy between May 2016 and February 2021. The two targeting techniques were localizing with anatomic landmarks or localizing with contrast enhancement.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Patel N et al. Clin Imaging. 2021 Jun 9. doi: 10.1016/j.clinimag.2021.06.004.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan Commentary: Prostate Cancer July 2021
Gate On Date
Mon, 06/07/2021 - 10:30
Un-Gate On Date
Mon, 06/07/2021 - 10:30
Use ProPublica
CFC Schedule Remove Status
Mon, 06/07/2021 - 10:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
sf322941.4
Activity ID
77695
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
xtandi [ 4408 ]